Soft tissue sarcoma
Conditions
Interventions
Drug elution embolism-Transcatheter arterial chemoembolization, DEB-TACE group:Drug elution embolism-Transcatheter arterial chemoembolization, DEB-TACE group
Arterial infusion chemotherapy group:Arterial infusion chemotherapy
Sponsors
The Fifth Medical Center of PLA General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age >= 14 years old, male or female; 2. Patients with metastatic or recurrent soft tissue sarcoma confirmed by histopathology; 3. The metastatic or recurrent lesion is not suitable or the patient does not undergo surgical resection; 4. Patients who have previously received or are about to receive interventional therapy; 5. According to the mRECIST standard for solid tumors, and the patient has at least one measurable lesion; 6. The Eastern Cancer Collaborative Group (ECOG) physical fitness score is 0-3 points; 7. The expected survival period is >= 3 months; 8. Subjects volunteered to join the study, signed the informed consent form, had good compliance and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. Abnormal coagulation function, INR>1.5, or undergoing anticoagulation therapy or known hemorrhagic diseases; 2. White blood cells2 × ULN 4. Abnormal liver function, ALT or ASL>5 × ULN 5. Have a history of major diseases involving the heart, kidney, bone marrow, or lung, central nervous system; 6. Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures; 7. Serious infection during the active period or under clinical control, or severe infection within 4 weeks before enrollment; 8. Interpretation of research results; 9. Have a mental disorder or a history of abuse of psychotropic substances and are unable to quit; 10. Clinical trials involving other investigational drugs or devices within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progressive free survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate, ORR;Disease control rate, DCR;1-year survival rate; | — |
Countries
China
Contacts
Public ContactJing Li
The Fifth Medical Center of PLA General Hospital
Outcome results
None listed